Researchers from the University of New Mexico have announced a scientific breakthrough in the journal Genomic Psychiatry, a finding that promises to significantly alter treatment strategies for neurodegenerative disorders, chiefly Alzheimer’s disease.
A primary factor implicated in Alzheimer’s disease is the accumulation of hazardous tau proteins within the brain, an aggregation responsible for neuronal destruction and the subsequent decline in cognitive abilities. Until now, the majority of scholarly endeavors concentrated on devising means to eliminate these particular proteins from brain tissue. However, the team at the University of New Mexico shifted focus to pinpointing the precise trigger initiating this buildup.
Their laboratory investigations successfully pinpointed the crucial involvement of the enzyme OTULIN. This specific enzyme acts as the principal controller for the biological pathways that lead to the formation of these detrimental tau protein aggregates. In controlled settings, by employing genetic manipulation techniques, the scientists managed to cease OTULIN production in aging mice. The consequence of this intervention was the complete disappearance of tau proteins from neurons, coupled with the restoration of optimal structure and function within the brain cells.
The study’s originators suggest that the OTULIN enzyme operates much like an “on/off switch” that initiates the mechanisms leading to mental degradation. They posit that inhibiting this enzyme could form the foundation for novel pharmaceuticals capable not only of halting the progression of Alzheimer’s but potentially reversing aspects of brain aging. The subsequent phase will involve clinical trials involving human subjects.
About the Author
